Management Team

Advisory Board


Dr. Doris Bucher, PhD, is an Associate Professor in the Dept. of Microbiology and Immunology at New York Medical College, Valhalla, NY. Dr. Bucher has dedicated most of her research career to work on influenza viruses and influenza vaccine development. Her laboratory at New York Medical College (NYMC) is one of only three laboratories worldwide which produce high growth reassortant ‘seed’ viruses for the influenza vaccine. For the past six years (including 2009-2010), the NYMC H3N2 reassortants have been used either exclusively or for the bulk of world production of 400-450 million doses of influenza vaccine (inactivated). With the onset of the swine influenza in late April, her laboratory group began development of a seed virus for H1N1v (swine origin, 2009). This reassortant, NYMC X-179A, as well as NYMC X-181, have been used as the seed viruses for most of the swine flu vaccine (inactivated, egg based) produced world-wide. The clinical trials showed that a protective immune response was achieved with a single dose of the X-179A vaccine. It is estimated that 1-2 billion doses of 2009 H1N1 vaccine will be produced.

Dr. Nathan Litman, MD, is Professor of Pediatrics at the Albert Einstein College of Medicine, and Director of Pediatrics and Pediatric Infectious Diseases at the Children’s Hospital at Montefiore. Dr. Litman has received numerous awards for teaching including from the pediatric house staff at Montefiore, from the Infectious Diseases fellows at Montefiore, from medical students at the Albert Einstein College of Medicine, and from the Pediatric Staff at Flushing Hospital; he has recently been named a “Master Teacher” by the Department of Pediatrics at Montefiore. Dr. Litman has a broad range of interests within the field of pediatric infectious diseases and is frequently consulted by pediatricians in practice. He has participated in clinical trials of several vaccines which are now part of the routine immunization schedule. He regularly is asked to give lectures to medical groups and hospitals throughout the region. Dr. Litman has been named several times in various lists of “Best Doctors in New York”. Dr. Litman was one of the co-authors on the initial article describing AIDS in children, and the acquisition of Rocky Mountain Spotted Fever in an urban environment. He has authored chapters in textbooks on sexually transmitted diseases, mumps, actinomycosis, nocardiosis, and viral infections. He serves as a reviewer for several medical journals.

Dr. Anjani Shah, PhD, has a PhD in cell biology and experience in medical writing and public relations. Her unique background enables her to approach projects from a variety of perspectives - which is the key to effective communications. Prior to starting her own biomedical writing and consulting practice, she was Director of Scientific Affairs for Targent Pharmaceuticals, a start-up specialty pharmaceutical company specializing in cancer. At Targent she developed its website, co-wrote its business plan, corporate presentations, summaries about its product pipeline and helped research licensing opportunities. Before joining Targent, Dr. Shah worked at Noonan/Russo Communications, a public relations company where she developed media and investor relations programs and corporate materials for biotechnology companies. She writes for non-profits, biotech companies and industry publications such as Drug Discovery and Development. She also produces scientific conferences in the biotech/pharma industry for Cambridge Healthtech Institute. She earned her Ph.D from the Albert Einstein College of Medicine in the area of signal transduction. Her undergraduate degree is from Princeton University where she majored in biology and earned a certificate in the program of Science in Human Affairs.

Dr. Stephen Udem, MD, PhD, is an internationally recognized virologist and vaccinologist, considered especially expert in the field of negative strand RNA viruses including such human respiratory disease pathogens as influenza. He previously was Vice President of Wyeth Vaccines Research and a member of the Wyeth Vaccine Business Unit's Senior Management Team charged with candidate identification, design, development, regulatory submission, intellectual property assessment, as well as U.S. and international product licensure. Thereafter, he served as Chief Scientific Officer and Senior Vice President of Vaccine Development of the International AIDS Vaccine Initiative before opting to start his own Vaccine R&D consultant/advisor practice. Prior to joining industry, Dr. Udem held senior academic positions at the Albert Einstein College of Medicine and the New Jersey Medical School. Dr. Udem's contributions have been extensively published in the scientific literature and many of his creative technology inventions have been patented. He received his undergraduate degree from the City College of New York and his Ph.D. and M.D. from the Albert Einstein College of Medicine.

Dr. Raphael P. Viscidi, MD, is a Full Professor of Pediatrics at Johns Hopkins University School of Medicine.  He is board certified in Infectious Diseases.  For over 25 years he has conducted clinical and laboratory research in Virology with an emphasis on viral pathogenesis, humoral immune responses to viruses and epidemiology of viral infections.  His research has focused primarily on human papillomaviruses and polyomaviruses, but also on human immunodeficiency virus and coronaviruses.  His laboratory has produced virus like particles for vaccine development and as reagents for antibody assays.  He is the Virology Editor of the journal Molecular and Cellular Probes.  He serves as a regular member of the National Institutes of Health Clinical Research and Field Studies of Infectious Diseases study section.  He has published over 160 peer-reviewed scientific papers and written over 25 book chapters.

Mr. Sohal Shah, BSc, A.C.A, Mr. Shah currently holds a senior position at JP Morgan Chase and has previously worked with Price Waterhouse in London, Hong Kong and New York City as well as with Cazenove, Merrill Lynch, and ING Barings. He has also been involved in the many aspects of establishing and growing small companies.  He holds an degree in Banking and International Finance from the City of London Business School.

Mr. William B. Kerr, Esq., is a partner in the Kerr&Richards, LLP law firm located in New York city. His legal expertise pans across the following fields: Financial Services Litigation, Private Equity, Environmental, Corporate Governance, Election & Campaign Finance. He holds a BSc in Agricultural Economics from Cornell University and a Law Degree from the University of Pennsylvania, as well as post-graduate courses at the London School of Economics.

Copyright © 2003-2009 TechnoVax. All rights reserved.   •   Website by AJ Network Solutions